Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statement of Loss and Comprehensive Loss (Unaudited)

v3.21.2
Condensed Consolidated Interim Statement of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenue $ 0 $ 0 $ 0 $ 0
Expenses:        
Research and development 9,831 6,866 18,059 12,800
General and administrative 3,657 9,015 11,681 14,915
Operating expenses 13,488 15,881 29,740 27,715
Other income (expense):        
Interest income 23 116 50 439
Foreign exchange gains/(losses) (5) 15 (7) 0
Total other income 18 131 43 439
Net loss (13,470) (15,750) (29,697) (27,276)
Other comprehensive gain/(loss):        
Unrealized loss on securities available-for-sale 0 (15) 0 (15)
Total comprehensive loss $ (13,470) $ (15,765) $ (29,697) $ (27,291)
Basic and diluted loss per common share (in dollars per share) $ (0.15) $ (0.21) $ (0.33) $ (0.36)
Weighted average number of common shares outstanding used in the calculation of (in thousands)        
Basic and diluted loss per common share (in shares) 88,946 76,275 88,915 76,251